AstraZeneca Pharma India MD Gagandeep Singh Bedi resigns, Sanjeev Panchal to take over

Sanjeev Panchal

AstraZeneca Pharma India Limited announced that Gagandeep Singh Bedi has resigned from the role of Managing Director and Director of the company, with effect from December 31, 2022. Sanjeev Panchal has been named new Additional Director and Managing Director of the company, with effect from January 1, 2023.

AstraZeneca India was established in 1979 and is headquartered at Bengaluru, Karnataka. AstraZeneca Pharma India Limited (AZPIL) is the operating company and covers manufacturing, sales and marketing activities of the company in India.

According to the company’s exchange filing, “This is to inform that the Board of Directors at its Meeting held today i.e., December 14, 2022, noted the Resignation of Mr. Gagandeep Singh Bedi (DIN: 07844333) from the Office of Managing Director and also as Director of the Company with effect from the closing of business hours on December 31, 2022. The Board of Directors of the Company has approved the appointment of Mr. Sanjeev Panchal (DIN: 09823879), as Additional Director and also as Managing Director of the Company for a period of three (3) years with effect from January 1, 2023 subject to the approvals of the Members of the Company through Postal Ballot and Central Government, if so needed.”

Sanjeev Panchal is a Science graduate (BSc) and he holds an MBA and Doctorate in Business Administration (PhD). He also has professional Diplomas in International Business and HRM.

He had joined AstraZeneca Pharma India Limited in February 2003 as Brand Associate and progressed through several positions in India, Indonesia, Asia Pacific and the International region, based in Singapore and the United Kingdom (UK).

Prior to his current role as CP Malaysia, Sanjeev was the Director for CVRM Commercial and CVMD Brand – International based out in United Kingdom (UK) between May 2017 to September 2019. Before his assignment to UK, Sanjeev played critical leadership roles in India such as BU Head for Brilinta and Interim BU Head Respiratory during 2014 to 2017.

Prior to his BU Head role, Sanjeev was managing portfolios of Sales & Marketing Director for Brilinta and Marketing Director – CV till 2010. Sanjeev was in an International assignment to Singapore as a Regional Marketing Manager – Respiratory & GI, Asia Pacific between 2009 to 2010. He was also an Interim Marketing Director for AZ Indonesia for 3 months International assignment in 2010.

In his role as a Country President of Malaysia, Sanjeev has significantly transformed the business and guided the team to return the company to growth, growing almost double the market at 25% in 2022, a statement said.

+ posts

HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.

What's your take on this post ? Comment: